SynthesisMedicine2017
Prognostic and clinicopathological significance of cyclin B expression in patients with breast cancer: A meta-analysis.
Synthesis in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- Biogenic copper oxide nanoparticles from Bacillus coagulans induced reactive oxygen species generation and apoptotic and anti-metastatic activities in breast cancer cells.Scientific reports · 2023Article
- Circular RNA circLAMA3 inhibits the proliferation of bladder cancer by directly binding an mRNA.Molecular therapy oncolytics · 2022Article
- Dehydrocrenatidine extracted fromOncology reports · 2021Article
- Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.Pharmaceutics · 2021Review
- EMI2 expression as a poor prognostic factor in patients with breast cancer.The Kaohsiung journal of medical sciences · 2020Article
- A prognostic model based on cell-cycle control predicts outcome of breast cancer patients.BMC cancer · 2020Article
- Chronic and Acute Toxicities of Aflatoxins: Mechanisms of Action.International journal of environmental research and public health · 2020Review
- Identification of Aurora Kinase A as a Biomarker for Prognosis in Obesity Patients with Early Breast Cancer.OncoTargets and therapy · 2020Article
- Silencing of heat shock protein 27 increases the radiosensitivity of non‑small cell lung carcinoma cells.Molecular medicine reports · 2019Article
- Potential role of cyclin F mRNA expression in the survival of skin melanoma patients: Comprehensive analysis of the pathways altered due to cyclin F upregulation.Oncology reports · 2018Article
- Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.Breast cancer research and treatment · 2018Article
- Divergent impact of actin isoforms on cell cycle regulation.Cell cycle (Georgetown, Tex.) · 2018Article
- Identification of potential core genes in triple negative breast cancer using bioinformatics analysis.OncoTargets and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyclin B plays a crucial role in cancer cell cycle progression and is overexpressed in many human cancers, including breast cancer. However, the prognostic value of cyclin B expression in breast cancer is controversial. We performed a meta-analysis to assess the clinicopathological and prognostic significance of cyclin B expression in breast cancer.
methodsWe searched PubMed, web of science, and Embase databases to retrieve the publications investigating the association between cyclin B expression and clinicopathological/prognostic significance in breast cancer patients. The pooled hazard ratio (HR) or odds ratio (OR) with its 95% confidence intervals (CIs) were used to estimate the effects.
resultsTen studies with 2366 breast cancer patients were included to evaluate the association between cyclin B expression and overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), and clinicopathological parameters. The results showed that cyclin B overexpression in breast cancer patients was significantly associated with both poor OS (univariate analysis: HR = 2.38, 95% CI = 1.72-3.30, P < .001), DFS (univariate analysis: HR = 1.86, 95% CI = 1.50-2.32, P < .001; multivariate analysis: HR = 1.75, 95% CI = 1.22-2.52, P = .003), and DSS (multivariate analysis: HR = 5.42, 95% CI = 2.15-13.66, P < .001). Additionally, cyclin B overexpression was significantly associated with lymphatic invasion (OR = 2.58, 95% CI = 1.03-6.46, P = .017).
conclusionCyclin B overexpression appears to be an independent potential prognostic marker to DSS and DFS for breast cancer. Further studies with large sample size are needed to dissect the relationship between cyclin B and clinicopathological features or prognosis of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.